Physician profile
John Hu
NPI 1649698127
$18,289.92
in general payments reported to CMS, 2019-2025
87 companies · $4,002 in 2025
The $4,002 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,335 · 2020: $967 · 2021: $1,780 · 2022: $3,087 · 2023: $3,656 · 2024: $3,462 · 2025: $4,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,935.13 |
| Education | $185.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,761.28 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $1,503.02 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,249.93 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Incyte Corporation | $758.93 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Biotech, INC. | $723.41 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Genentech USA, INC. | $625.04 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Celgene Corporation | $623.48 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $593.89 | 2020-2025 | Opdivo, Opdualag, Abilify |
| Pfizer INC. | $570.22 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $512.62 | 2021-2025 | Alunbrig, Fruzaqla, Iclusig |
| Astellas Pharma US INC | $448.25 | 2020-2025 | Vyloy, Xtandi, Padcev |
| Genzyme Corporation | $432.99 | 2019-2025 | |
| Abbvie INC. | $392.91 | 2022-2025 | |
| Daiichi Sankyo INC. | $369.56 | 2020-2025 | Enhertu, Vanflyta |
| Glaxosmithkline, LLC. | $368.36 | 2020-2025 | Ojjaara, Jemperli, Shingrix |
Show all 86 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $361.08 | 2021-2025 | Trodelvy |
| Exelixis INC. | $334.36 | 2019-2025 | Cabometyx |
| Eisai INC. | $311.83 | 2020-2025 | |
| Beigene USA, INC. | $300.10 | 2020-2025 | Brukinsa, Tevimbra |
| Ipsen Biopharmaceuticals, INC | $282.77 | 2019-2025 | Somatuline Depot, Onivyde |
| Karyopharm Therapeutics INC. | $273.37 | 2021-2025 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $263.81 | 2020-2025 | |
| Lilly USA, LLC | $251.74 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Alexion Pharmaceuticals, INC. | $242.70 | 2019-2025 | Ultomiris |
| Puma Biotechnology, INC. | $238.35 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $236.23 | 2022-2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $234.44 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Pharmacyclics LLC, An Abbvie Company | $233.99 | 2020-2023 | Imbruvica |
| Aveo Pharmaceuticals, INC. | $226.71 | 2021-2025 | Fotivda |
| Amgen INC. | $218.10 | 2019-2025 | Kyprolis, Nplate, Vectibix |
| Coherus Oncology, INC. | $193.89 | 2021-2025 | Loqtorzi, Udenyca |
| Pharmaessentia USA Corporation | $184.73 | 2022-2025 | Besremi |
| Seagen INC. | $171.83 | 2021-2023 | Adcetris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.74 | 2020-2025 | Gilotrif |
| Blueprint Medicines Corporation | $139.36 | 2021-2024 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $135.78 | 2021-2024 | Qinlock |
| Array Biopharma INC | $135.27 | 2022-2025 | Mektovi, Braftovi, Xalkori |
| Beone Medicines USA, INC. | $111.65 | 2025 | Brukinsa, Tevimbra |
| Taiho Oncology, INC. | $109.16 | 2023-2025 | |
| Emd Serono, INC. | $102.91 | 2021-2025 | Bavencio |
| Sobi, INC | $99.78 | 2022-2025 | |
| Stemline Therapeutics INC. | $85.28 | 2023-2024 | Orserdu, Elzonris |
| Morphosys, US INC. | $82.19 | 2021-2023 | Monjuvi |
| Janssen Pharmaceuticals, INC | $81.58 | 2021-2023 | Xarelto |
| Servier Pharmaceuticals LLC | $81.37 | 2022-2024 | |
| Kite Pharma, INC. | $78.68 | 2023-2024 | Yescarta |
| Mylan Institutional INC. | $73.14 | 2021-2022 | |
| Mirati Therapeutics, INC. | $62.11 | 2023-2024 | Krazati |
| Tempus Ai, INC | $59.84 | 2024 | |
| Jazz Pharmaceuticals INC. | $58.97 | 2023-2025 | |
| Legend Biotech USA INC. | $56.70 | 2024-2025 | Carvykti |
| Amag Pharmaceuticals, INC. | $53.89 | 2021 | |
| Genmab U.S., INC. | $51.42 | 2023-2025 | Epkinly |
| Tersera Therapeutics LLC | $51.11 | 2020-2024 | Quzyttir |
| Adc Therapeutics America, INC. | $49.90 | 2023-2025 | |
| Recordati_rare_diseases_inc. | $47.22 | 2024-2025 | Sylvant |
| Iovance Biotherapeutics, INC. | $46.63 | 2025 | Amtagvi |
| Octapharma USA, INC. | $46.51 | 2023 | Panzyga |
| Springworks Therapeutics, INC. | $45.95 | 2024-2025 | Ogsiveo |
| Myovant Sciences INC. | $45.40 | 2021 | |
| Agios Pharmaceuticals, INC. | $43.99 | 2023-2025 | Pyrukynd |
| Cti Biopharma Corp. | $43.19 | 2023 | Vonjo |
| Epizyme, INC. | $42.43 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $41.13 | 2023 | Firdapse |
| Ge Healthcare | $38.16 | 2025 | |
| Eusa Pharma (US) LLC | $36.77 | 2020-2022 | |
| Acrotech Biopharma INC. | $34.15 | 2021-2022 | |
| Immunogen, INC. | $27.93 | 2023 | Elahere |
| Adaptive Biotechnologies Corporation | $24.81 | 2023 | Clonoseq |
| Tg Therapeutics, INC. | $24.02 | 2021 | |
| Geron Corporation | $22.50 | 2024 | Rytelo |
| Biocon Biologics INC | $22.28 | 2024 | Fulphila |
| Csl Behring | $21.44 | 2023 | Idelvion, Afstyla |
| Immunocore Limited | $21.01 | 2024 | Kimmtrak |
| Fennec Pharmaceuticals, INC. | $20.23 | 2025 | Fyarro |
| Apellis Pharmaceuticals, INC. | $20.08 | 2025 | Empaveli |
| Pharmacosmos Therapeutics INC. | $19.92 | 2025 | Monoferric |
| Aurobindo Pharma USA, INC. | $19.81 | 2020 | |
| Alnylam Pharmaceuticals INC. | $18.97 | 2023 | Givlaari |
| Foundation Medicine, INC. | $17.45 | 2023 | |
| Sanofi-Aventis U.S. LLC | $16.98 | 2020 | |
| Azurity Pharmaceuticals, INC. | $16.31 | 2025 | Danziten |
| Syndax Pharmaceuticals, INC. | $16.18 | 2025 | |
| Chiesi USA, INC. | $14.92 | 2024 | Ferriprox |
| Sirtex Medical INC | $13.63 | 2020 | |
| Dova Pharmaceuticals | $13.17 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Keytruda $1,201Reblozyl $418Kisqali $352Enhertu $343Jakafi $282Lynparza $239Opdivo $236Imfinzi $224Imbruvica $218Lenvima $201Darzalex $197Brukinsa $196Alunbrig $192Tecvayli $191Xpovio $190Calquence $188Monjuvi $184Adcetris $177Elahere $154Libtayo $153Besremi $150Tavalisse $142Rezlidhia $142Fruzaqla $139Fotivda $137Jaypirca $133Opdualag $130Venclexta $130Epkinly $129Xtandi $127Cabometyx $119Nerlynx $114Mektovi $113Piqray $111Inqovi $109Lonsurf $109Pluvicto $108Ayvakit $107Verzenio $106Fabhalta $103Tukysa $101Elrexfio $99.04Braftovi $98.25Tivdak $97.78Gilotrif $97.11Trodelvy $96.43Udenyca $96.06Somatuline Depot $92.60Onivyde $92.60Tevimbra $86.14Welireg $85.90Scemblix $82.98Loqtorzi $81.95Pemazyre $81.65Sarclisa $81.27Ibrance $78.14Polivy $76.14Talvey $75.20Tecentriq $72.90Nubeqa $72.33Iclusig $72.28Mekinist $69.58Erleada $66.90Xalkori $66.47Lorbrena $66.47Vyloy $65.79Talzenna $64.99Orgovyx $64.99Gavreto $64.48Orserdu $64.27Qinlock $62.38Krazati $62.11Ultomiris $61.82Vonjo $59.86Zepzelca $58.97Lunsumio $57.45Padcev $57.14Tibsovo $56.91Lutathera $55.20Yescarta $51.07Abilify $48.59Sylvant $47.22Bosulif $47.14Phesgo $46.95Amtagvi $46.63Panzyga $46.51Ogsiveo $45.95Itovebi $45.64Doptelet $44.92Pyrukynd $43.99Rybrevant $41.56Firdapse $41.13Comirnaty $38.82Kyprolis $38.33Idhifa $38.09Bavencio $33.36Xospata $33.33Tagrisso $32.69Cuvitru $30.07Columvi $29.51
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.